DEPO-PROVERA® (Non-English)

DEPO-PROVERA® is an injectable contraceptive containing medroxyprogesterone acetate, a synthetic form of progesterone. It prevents pregnancy by suppressing ovulation, thickening cervical mucus, and altering the uterine lining. Each injection provides three months of contraceptive protection. Additionally, DEPO-PROVERA® is used to treat endometriosis and certain types of cancer, including breast, kidney, and endometrial cancer. While effective, it does not protect against sexually transmitted infections (STIs), and its prolonged use can lead to bone density reduction​.

Key Features:

• Highly Effective Contraceptive – 99% effectiveness in preventing pregnancy with one injection every three months.
• Additional Medical Uses – Treats endometriosis and hormone-sensitive cancers.
• Long-Term Effects – May reduce bone density, requiring monitoring for osteoporosis risk​.

DEPO-PROVERA® is supplied in single-use vials containing a white, cloudy liquid. Each vial contains medroxyprogesterone acetate in a sterile suspension.

Packaging Details:

• Available in 150 mg/1 mL vials for intramuscular injection.
• Each vial is labeled with an Australian Register Number for identification (AUST R 12300).
• Supplied in a tamper-proof carton, ensuring sterility​.

Ingredients:

• Active Ingredient: Medroxyprogesterone acetate – a synthetic progestogen.
• Inactive Ingredients:
  • Macrogol 3350 – Enhances solubility.
  • Polysorbate 80 – A stabilizing agent.
  • Sodium chloride – Maintains isotonic balance.
  • Methyl hydroxybenzoate & Propyl hydroxybenzoate – Preservatives.
  • Water for Injection – Diluent​.

DEPO-PROVERA® is indicated for contraception, endometriosis, and cancer treatment.

Indications:

• Contraception:
  • 150 mg intramuscular injection every 3 months.
  • First dose should be given within 5 days of the menstrual cycle start.
  • Provides immediate contraceptive protection if administered correctly.
• Endometriosis:
  • 50 mg weekly or 100 mg every two weeks.
  • Treatment usually lasts at least 6 months.
• Cancer Treatment:
  • Breast cancer: 500 mg daily for 4 weeks, then 500–1000 mg weekly.
  • Other cancers (kidney, endometrial): 600–1200 mg per week, followed by 450–600 mg every 1–4 weeks​.

Contraindications:

• History of blood clots, stroke, or severe liver disease.
• Unexplained vaginal bleeding or undiagnosed breast lumps.
• Pregnancy or planning to become pregnant​.

Common Side Effects:

• Menstrual changes: Irregular bleeding, spotting, or amenorrhea.
• Weight fluctuations: Possible increase or decrease in body weight.
• Bone density reduction: Risk of osteoporosis with long-term use.
• Mood changes: Depression, fatigue, or dizziness.
• Injection site reactions: Mild swelling or discomfort​.

DEPO-PROVERA® is administered as an intramuscular injection by a healthcare professional.

Administration Guidelines:

• Contraceptive use: 150 mg every 3 months in the buttock or upper arm muscle.
• Endometriosis treatment: 50 mg weekly or 100 mg biweekly.
• Cancer treatment: Higher doses, typically 500 mg to 1200 mg weekly, based on medical condition.
• Injection timing: If switching from oral contraceptives, administer within 7 days after the last active pill.
• Missed dose: If the interval exceeds 14 weeks, pregnancy testing is required before re-administration​.

Storage Instructions:

• Store below 30°C, in a dry, cool place.
• Do not freeze or expose to excessive heat.
• Unused or expired vials should be returned to a pharmacist for disposal​.

Warning! The product is intended solely for professional use in a medical environment and under professional supervision. The product is supplied to medical professionals who specialize in aesthetic medicine (plastic surgery, facial treatments) and work under individual medical licenses as aestheticians or in dedicated clinics. Unprofessional use by individuals without a medical background may lead to severe adverse effects and health harm.